Lifetime Use of Classic Psychedelics Could Decrease Risk of Hypertension

Research recently reported in “Hypertension” has found that lifetime use of classic psychedelics may be associated with a lower risk of hypertension.

Otto Simonsson, from University of Oxford’s department of sociology, stated that the findings demonstrated that classic psychedelic use was linked to a 14% lower chance of hypertension, adding that lifetime use of tryptamine was linked to a 20% lower chance of hypertension.

Simonsson and his colleagues noted that these results may be valuable in helping understand the physical health after effects of classic psychedelic use, with randomized controlled trials being conducted to look into the possible ways that classic psychedelics affect blood pressure.

For this investigation, the scientists used data obtained from the National Survey on Drug Use and Health, as a representative of the adult population in the United States, to find out the relationship between hypertension and lifetime classic psychedelic use. The psychedelics included in the analysis were phenethylamine, LSD, psilocybin, ayahuasca and DMT.

The study found that lifetime psychedelic use was often reported among individuals who reported the following:

  • A history of anxiety or depression
  • Use of alcohol for the first time before they were 20 years
  • Lifetime use of tobacco
  • Lifetime use of other illegal substances
  • Usually took part in risky behavior
  • separated/ divorced or had never been married
  • Greater income
  • Greater educational attainment
  • Non-Hispanic Alaska native/American Indian or non-Hispanic white ethnicity
  • Middle-aged

Researchers discovered that among the three psychedelics classes, only lifetime use of tryptamine was linked to lower chances of hypertension.

The researchers explained that tryptamines had demonstrated their affinity for serotonin 1A receptor. The serotonin 1A receptor is linked to antidepressant and potentially antihypertensive effects when it’s stimulated and could provide a pharmacological explanation for the results observed in the study.

Additionally, the researchers continued, prior research proposed that the use of tryptamine had great therapeutic potential with respect to mental health, which could help explain why lifetime use of tryptamine had the strongest link to hypertension in the last year among the three classic psychedelics classes.

Even after the researchers adjusted the results for history of depression and anxiety, the results remained unchanged. The researchers then carried out a secondary investigation that adjusted for how recently a psychedelic had been used. They found that the only drug that had been used recently was LSD, adding that the data did not alter the initial results.

Research such this is doing a lot to advance the cause of psychedelic policy reform in different jurisdictions around the world. Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) is in the thick of psychedelic science as its teams are hard at work developing psychedelic treatment protocols as well as medicines.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050